Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Marinus Pharmaceuticals Inc. Fell as Much as 20.1% Today

By Maxx Chatsko - Aug 2, 2018 at 2:48PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The small biopharma announced second-quarter 2018 results and gave a business update.

What happened

Shares of Marinus Pharmaceuticals (MRNS 2.00%) dropped over 20% today after the company announced second-quarter 2018 results and provided an update on the state of its business. As an early-stage drug developer, there isn't much to report in terms of financial performance. The company doesn't generate revenue of any kind, so investors are more concerned with the cash position and with how much cash is burned in operations.

Therein may lie the problem. Marinus Pharmaceuticals exited June with approximately $46 million in cash and cash equivalents. Management said it expects that amount of cash to be sufficient to fund operations into 2020. Wall Street is raising eyebrows at that statement, as the biopharma has four studies in phase 2 or later. More importantly, it just delayed the data readout from one study, now expecting to provide an update in the fourth quarter of 2018 instead of the third quarter.

As of 2:21 p.m. EDT, the stock had recovered significantly, settling to a 6.6% loss.

A scientist sitting at a lab bench with a deflated look on his face

Image source: Getty Images.

So what

On one hand, the math does work out to support management's statement. Marinus Pharmaceuticals burned through about $11 million in cash in the first half of 2018. Maintaining an equivalent rate of cash burn, its $46 million would fund about eight more quarters of operation, through June 2020.

On the other hand, running mid- and late-stage clinical trials will be expensive. That suggests that the rate of cash burn will accelerate, and that $46 million might go quicker than investors may think. Furthermore, considering Marinus Pharmaceuticals has no track record to speak of (it was a penny stock not that long ago), Wall Street is worried that the recent data release delay is a sign of inexperience, and therefore more risk during this critical time in the company's history.

Now what

A single one-quarter delay isn't the end of the world, and doesn't seem to jeopardize the balance sheet. The real driver of the stock and the company's fate will be the performance of its one and only drug candidate ganaxolone. If it continues to perform well in clinical trials, then raising money -- or finding a development or commercialization partner -- will be relatively easy to do.

Marinus Pharmaceuticals has ridden the drug candidate this far, but investors are hoping for even better things to come. They may get an answer in the fourth quarter of 2018, when top-line data are reported for two of the four ongoing studies.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Marinus Pharmaceuticals, Inc. Stock Quote
Marinus Pharmaceuticals, Inc.
MRNS
$5.10 (2.00%) $0.10

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
356%
 
S&P 500 Returns
124%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.